{
}
Raphael Schicho, an analyst at Raiffeisen Bank International AG, maintains a "Buy" recommendation for Novo Nordisk shares despite recent momentum loss due to production issues and generic competition. The valuation has become attractive, and the earnings outlook remains promising, prompting a price target adjustment to DKK 1,000.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton highlighted concerns regarding supply chain bottlenecks, the timing for new capacity, and the progress on the planned acquisition of Catalent during a recent investor conference.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton highlighted concerns regarding supply chain bottlenecks, the timing for new capacity, and the progress on the planned acquisition of Catalent following an investor conference. Novo Nordisk has seen a remarkable gain of 4,254% since its first recommendation.
UBS has raised its target price for Coloplast to DKK 858 while maintaining a sell position. Coloplast A/S focuses on disposable medical products, with sales divided into hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and vocal and respiratory care (7.9%). Geographically, sales are distributed across Denmark (1.4%), the USA (21%), the UK (14%), France (10.8%), and other regions (52.8%).
Bayer faces legal and financial challenges but shows potential with innovative drugs like Eylea and elinzanetant. BioNxt Solutions is advancing in drug delivery systems and MS treatments, while Novo Nordisk reports strong sales growth amid increasing competition and patent expirations.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a slight upward trend in prescriptions for the weight loss drug Wegovy in the USA, especially after its recent removal from the list of scarce drugs. Since its initial recommendation, Novo Nordisk's stock has risen by 4.270%.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a slight upward trend in prescriptions for the weight loss drug Wegovy in the USA, with data expected to improve following its removal from the list of scarce drugs.
Novo Nordisk's Ozempic and Wegovy have transformed from diabetes treatments to weight-loss phenomena, driving the company's revenue to unprecedented heights, with a projected DKK 232 billion in 2023. However, soaring demand has led to shortages, impacting diabetes patients and prompting the company to halt insulin pen distribution in some regions. As Novo Nordisk prepares to launch CagriSema, the global obesity market is expected to reach $37.06 billion by 2031, with GLP-1 receptor agonists dominating.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton projects a growth rate of 23% for 2025, surpassing the market's expectation of 20%. Novo Nordisk has seen a remarkable 4,176% increase since its initial recommendation.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a price target of 1,100 Danish crowns. Analyst Jo Walton projects a growth rate of 23% for 2025, slightly above the market expectation of 20%. The analysis follows discussions among analysts regarding the company's future growth prospects.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
vo nordisk shares recommended as buy despite recent production challenges
14:56 13.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
14:39 13.11.2024
UBS maintains neutral rating for Novo Nordisk with target price of 1100 kroner
13:51 13.11.2024
ubs raises coloplast target price while maintaining sell position
09:58 13.11.2024
healthcare companies navigate challenges and opportunities in innovative drug development
09:00 12.11.2024
UBS maintains neutral rating for Novo Nordisk with target price of 1100 kroner
15:50 11.11.2024
ubs maintains neutral rating on novo nordisk with target price of 1100 kroner
14:52 11.11.2024
Novo Nordisk's weight loss drugs drive soaring demand and market shortages
Danish Krone
United States Dollar
Euro
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Eli Lilly and Company
Chiesi Farmaceutici S.p.A.
USA
ITA
ZAF
DNK
Elon Musk
Joe Biden
Andy Cohen
Show more
15:00 10.11.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
20:22 07.11.2024
ubs maintains neutral rating for novo nordisk with 1100 kroner target
20:22 07.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: